Analysis Tools
immune system
|
• dendritic cell maturation mediated by injections of TLR9 agonists is diminished in these mice
• maturation markers on DCs such as I-Ab, CD80, and CD86 have several fold lower expression than in controls
|
|
• less Th1 T cells develop when nave antigen-specific T cells are transferred into these mice with cognate antigen and a TLR9 agonist
|
|
• antigen specific IgG1 levels are lower by almost an order of magnitude compared to controls after immunization with OVA-peptide and TLR9 agonist
|
|
• antigen specific IgG2b levels are lower by an order of magnitude compared to controls after immunization with OVA-peptide and TLR9 agonist
|
|
• antigen specific IgG2c levels are lower by several orders of magnitude than controls after immunization with OVA-peptide and TLR9 agonist
|
|
• NK cells in vivo make much several fold less IFN-gamma in response to injections of TLR9 agonists
• there is also a reduction in IFN-gamma production upon LPS administration
|
|
• mice fail to make IL-12p40 in response to the TLR9 agonist CpG-containing oligodeoxynucleotide ODN1826
• IL-12p40 production is reduced 5- to 30- fold in response to agonists to TLR1 +TLR2, TLR4, TLR5, TLR7, or TLR9
|
|
• circulating levels of IL-6 one hour after TLR9 stimulation is half that in wild-type controls
|
|
• DCs fail to secrete cytokines in response to TLR9 agonists
|
|
• nave antigen-specific T cells expand at a much slower rate when transferred into these mice with cognate antigen and TLR9 agonist
|
homeostasis/metabolism
|
• mice fail to make IL-12p40 in response to the TLR9 agonist CpG-containing oligodeoxynucleotide ODN1826
• IL-12p40 production is reduced 5- to 30- fold in response to agonists to TLR1 +TLR2, TLR4, TLR5, TLR7, or TLR9
|
|
• circulating levels of IL-6 one hour after TLR9 stimulation is half that in wild-type controls
|
hematopoietic system
|
• dendritic cell maturation mediated by injections of TLR9 agonists is diminished in these mice
• maturation markers on DCs such as I-Ab, CD80, and CD86 have several fold lower expression than in controls
|
|
• less Th1 T cells develop when nave antigen-specific T cells are transferred into these mice with cognate antigen and a TLR9 agonist
|
|
• antigen specific IgG1 levels are lower by almost an order of magnitude compared to controls after immunization with OVA-peptide and TLR9 agonist
|
|
• antigen specific IgG2b levels are lower by an order of magnitude compared to controls after immunization with OVA-peptide and TLR9 agonist
|
|
• antigen specific IgG2c levels are lower by several orders of magnitude than controls after immunization with OVA-peptide and TLR9 agonist
|
|
• NK cells in vivo make much several fold less IFN-gamma in response to injections of TLR9 agonists
• there is also a reduction in IFN-gamma production upon LPS administration
|
cellular
|
• dendritic cell maturation mediated by injections of TLR9 agonists is diminished in these mice
• maturation markers on DCs such as I-Ab, CD80, and CD86 have several fold lower expression than in controls
|
